The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments

International Journal of Pharmaceutics

Volumn 200, Issue 2, 2000, Pages 279-288

  Michael, Yonatan ^a   Chowdhry, Babur Z ^a   Ashurst, Ian C ^b   Snowden, Martin J ^a   Davies Cutting, Craig ^b   Gray, Steven ^b  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

CFC 113; Deposition; ESI MS; Fluorescence; Fluticasone propionate; HPLC; Methanol water; Salmeterol xinafoate; UV Vis

Indexed keywords

ANTIASTHMATIC AGENT; FLUTICASONE PROPIONATE; SALMETEROL; SALMETEROL XINAFOATE; SOLVENT;

AQUEOUS SOLUTION; ARTICLE; DISPERSION; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUTION; FLUORESCENCE; FLUORESCENCE SPECTROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METERED DOSE INHALER; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY;

ALBUTEROL; ANDROSTADIENES; CHLOROFLUOROCARBONS, METHANE; MASS SPECTROMETRY; METHANOL; REFERENCE STANDARDS; SOLVENTS; SPECTROPHOTOMETRY, ULTRAVIOLET; WATER;

EID: 0034630869     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00397-5     Document Type: Article

References (13)

1. Austin R.P., Barton P., Davis A.M., Manners C.N., Stansfield M.C. The effect of ionic strength on liposome-buffer and 1-octanol-buffer distribution coefficients. J. Pharm. Sci. 87:1998;599-607.
2. Chilton A.S., Godward R.E., Carey P.F. The determination in human plasma of 1-hydroxy-2-naphthoic acid followed administration of salmeterol xinafoate. J. Pharm. Biomed. Anal. 13:1995;165-169.
3. Colthup P.V., Young G.C., Felgate C.C. Determination of salmeterol in rat and dog plasma by high-performance liquid chromatography with fluorescence detector. J. Pharm. Sci. 82:1993;323-325.
4. D'Alonzo G.E., Tolep K.A. Salmeterol in the treatment of chronic asthma. Am. Family Physician Clin. Pharmacol. 56:1997;558-562.
5. Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms. Eur. Respir. Rev. 7:1997;338-343.
6. Fuller R., Johnson M., Bye A. Fluticasone propionate - an update on preclinical and clinical experience. Respir. Med. 89:1995;3-18.
7. Jack D. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other-adrenoceptor agonists. Br. J. Clin. Pharmacol. 31:1991;501-514.
8. Johnson M. Salmeterol. Med. Res. Rev. 15:1995;225-257.
9. Johnson M. The anti-inflammatory profile of fluticasone propionate. Allergy. 50:1995;11-14.
10. Li Y.N.B., Tattam B.N., Brown K.F., Seale J.P. A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry. J. Pharm. Biomed. Anal. 16:1997;447-452.
11. Mistry N., Ismail I.M., Smith M.S., Nicholson J.K., Lindon J.C. Characterisation of impurities in bulk drug batches of fluticasone propionate using direct coupled HPLC-NMR spectroscopy and HPLC-MS. J. Pharm. Biomed. Anal. 16:1997;697-705.
12. Mistry N., Ismail I.M., Farrant R.D., Nicholson J.K., Lindon J.C. Impurity profiling in bulk pharmaceutical batch using 19F NMR spectroscopy and distinction between monomeric and dimeric impurities by NMR-based diffusion measurements. J. Pharm. Biomed. Anal. 19:1999;511-517.
13. Weersink E.J.M., Douma R.R., Postma D.S., Koter G.H. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am. J. Respir. Crit. Care Med. 155:1997;1241-1246.